BioRestorative Therapies, Inc. (BRTX)
NASDAQ: BRTX · IEX Real-Time Price · USD
1.650
-0.020 (-1.20%)
Jul 19, 2024, 4:00 PM EDT - Market closed
BioRestorative Therapies Revenue
BioRestorative Therapies had revenue of $149.50K in the twelve months ending March 31, 2024, with 10.66% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $35.00K with 11.82% year-over-year growth. In the year 2023, BioRestorative Therapies had annual revenue of $145.80K with 21.70% growth.
Revenue (ttm)
$149.50K
Revenue Growth
+10.66%
P/S Ratio
74.72
Revenue / Employee
$13,591
Employees
11
Market Cap
11.17M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 145.80K | 26.00K | 21.70% |
Dec 31, 2022 | 119.80K | 73.80K | 160.43% |
Dec 31, 2021 | 46.00K | -31.00K | -40.26% |
Dec 31, 2020 | 77.00K | -53.00K | -40.77% |
Dec 31, 2019 | 130.00K | 19.00K | 17.12% |
Dec 31, 2018 | 111.00K | 30.00K | 37.04% |
Dec 31, 2017 | 81.00K | 44.65K | 122.80% |
Dec 31, 2016 | 36.36K | -592.56K | -94.22% |
Dec 31, 2015 | 628.92K | 212.92K | 51.18% |
Dec 31, 2014 | 416.00K | 414.32K | 24,661.67% |
Dec 31, 2013 | 1.68K | -13.91K | -89.22% |
Dec 31, 2012 | 15.59K | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
RedHill Biopharma | 6.53M |
Senti Biosciences | 1.28M |
Traws Pharma | 226.00K |
Inhibikase Therapeutics | 195.98K |
Vaccinex | 124.00K |
Cardio Diagnostics Holdings | 32.99K |
BRTX News
- 25 days ago - BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program - GlobeNewsWire
- 5 weeks ago - BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 5 weeks ago - BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program - GlobeNewsWire
- 6 weeks ago - BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference - GlobeNewsWire
- 2 months ago - BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice - GlobeNewsWire
- 2 months ago - BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market - Accesswire
- 2 months ago - BioRestorative Therapies Provides First Quarter 2024 Business Update - GlobeNewsWire
- 2 months ago - BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity - GlobeNewsWire